Application of interferon beta-1b in multiple sclerosis

European Neurological Review

Volumn 6, Issue 1, 2011, Pages 36-44

  Bagnato, Francesca ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

(IFN 1b); Inflammation; Interferon beta 1 ; Magnetic resonance imaging (MRI); Multiple sclerosis; Neurodegeneration

Indexed keywords

EID: 84858174538     PISSN: 17583837     EISSN: 17583845     Source Type: Journal    
DOI: 10.17925/ENR.2011.06.01.36     Document Type: Article

References (63)

1. Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways, Lancet Neurol, 2010;9:727-39.
2. Lassmann H, The pathologic substrate of magnetic resonance alterations in multiple sclerosis, Neuroimaging Clin N Am, 2008;18:563-76.
3. Nightingale SL, From the Food and Drug Administration, JAMA, 1993;270:1672.
4. Tomassini V, De Giglio L, Reindl M, et al., Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS, Mult Scler, 2007;13:1086-94.
5. Fisniku LK, Brex PA, Altmann DR, et al., Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain, 2008;131:808-17.
6. McFarland HF, Frank JA, Albert PS, et al., Using gadolinium-enhanced magnetic resonance imaging lesions to monitor the activity in multiple sclerosis, Ann Neurol, 1992;32:758-66.
7. Kappos L, Moeri D, Radue EW, et al., Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group, Lancet, 1999;353:964-9.
8. Thompson AJ, Kermode AG, Wicks D, et al., Major differences in the dynamics of primary and secondary progressive multiple sclerosis, Ann Neurol, 1991;29:53-62.
9. Bagnato F, Jeffries N, Richert ND, et al., Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years, Brain, 2003;126:1782-9.
10. Van Waesberghe JH, Kamphorst W, De Groot CJ, et al., Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability, Ann Neurol, 1999;46:747-54.
11. Riva M, Ikonomidou VN, Ostuni JJ, et al., Tissue-specific imaging is a robust methodology to differentiate in vivo t1 black holes with advanced multiple sclerosis-induced damage, AJNR, 2009;30:1394-401.
12. Sailer M, Fischl B, Salat D, et al., Focal thinning of the cerebral cortex in multiple sclerosis, Brain, 2003;126:1734-44.
13. Bagnato F, Butman J, Gupta S, et al., Cortical plaques in patients with multiple sclerosis: in vivo MRI study, AJNR, 2006;27:2161-7.
14. Confavreux C, Vukusik S, Natural history of multiple sclerosis: a unifying concept, Brain, 2006;129:606-16.
15. Kurtzke JF, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 1983;33:1444-52.
16. Cutter GR, Baier ML, Rudick RA, et al., Development of a multiple sclerosis functional composite as a clinical trial outcome measure, Brain, 1999;122:871-82.
17. Bagnato F, Frank JA, The role of nonconventional magnetic resonance imaging techniques in demyelinating disorders, Curr Neurol Neurosci Rep, 2003;3:238-45.
18. Miller DH, Barkhof F, Frank JA, et al., Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance, Brain, 2002;125:1676-95.
19. Polman CH, Reingold SC, Barkhof F, et al., Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment, Neurology, 2008;70:1134-40.
20. Kappos L, Polman CH, Freedman MS, et al., Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndrome, Neurology, 2006;67:1242-9.
21. The IFNB Multiple Sclerosis Study Group, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 1993;43:655-61.
22. Kappos L, European Study Group on interferon beta-1b in secondary progressive MS, Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis, Lancet, 1998;7:352:1491-7.
23. O' Connor P, Arnason B, Comi G, et al., 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study, Lancet Neurol, 2009;8:889-97.
24. Koch-Henriksen N, Sorensen PS, Christsensen T, et al., A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis, Neurology, 2006;66:1056-60.
25. Etemadifar M, Janghorbani M, Shaygannejad V, Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis, Acta Neurol Scand, 2006;113:283-7.
26. Fletcher S, Vardi J, Pollak L, et al., Comparison of glatimerar acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up, J Neurol Sci, 2002;197:51-5.
27. Durelli L, Verdun E, Barbero P, et al., Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN), Lancet, 2002;359:1453-60.
28. Panitch H, Miller A, Paty D, et al., Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study, Neurology, 2004;63:1788-95.
29. Kappos L, Freedman MS, Polman CH, et al., Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurol, 2009;8:987-97.
30. The IFNB Multiple Sclerosis Study group and the University of British Columbia MS/MRI Analysis Group, Interferon beta-1b in the treatment of multiple sclerosis; final outcome of the randomized controlled trial, Neurology, 1995;45:1277-85.
31. Kappos L, Polman C, Pozzilli C, et al., Final analysis of the European multicenter trial on IFN beta-1b in secondary-progressive MS, Neurology, 2001;57:1969-75.
32. Montalban X, Sastre-Garriga J, Tintoré M, et al., A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis, Mult Scler, 2009;15:1195-205.
33. Solari A, Radice D, Manneschi L, et al., The multiple sclerosis functional composite: different practice effects in the three test components, J Neurol Sci, 2005;228:71-4.
34. Ebers GC, Traboulsee A, Li D, et al., Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial, J Neurol Nuerosurg Psychiatry, 2010;81(8):907-12.
35. Bonzano L, Roccatagliata L, Mancardi GL, et al., Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?, Mult Scler, 2009;15:1043-7.
36. Paty DW, Li DK, The UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group, Interferon beta-1b is effective in relapsing remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 1993;43:662-7.
37. Sormani MP, Bruzzi P, Beckmann K, et al., MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b, Neurology, 2003;60:1462-6.
38. Sormani MP, Bruzzi P, Beckmann K, et al., The distribution of magnetic resonance imaging response to interferon beta-1b in multiple sclerosis, J Neurol, 2005;252:1455-8.
39. Stone LA, Frank JA, Albert PS, et al., The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis, Ann Neurol, 1995;37:611-9.
40. Gupta S, Solomon J, Tasciyan T, et al., Interferon beta effects on re-enhancing lesions in patients with multiple sclerosis, Mult Scler, 2005;11:658-68.
41. Bagnato F, Gupta S, Richert ND, et al., Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations, Arch Neurol, 2005;62:1684-8.
42. Chiu A, Richert N, Ehrmantraut M, et al., Heterogeneity in the imaging response patterns to interferon beta in patients with multiple sclerosis: a 3-year study with monthly imaging, Arch Neurol, 2009;66:39-43.
43. Bagnato F, Jeffries N, Richert N, et al., Interferon beta therapy does not affect duration in time of Gd-enhancing lesions and black holes in relapsing remitting multiple sclerosis [Abstract], American Academy of Neurology, 55th Annual Meeting, Honolulu, HI, 2003.
44. Filippi M, Rocca MA, Camesasca F, Interferon beta-1b compared with GA therapy for reducing evolution of permanent T1 hypointensities (black holes) on brain MRI in treatment-naïve RRMS patients [Abstract], American Academy of Neurology, 62th Annual Meeting, Toronto, Canada, April 2010.
45. Brex PA, Molyneux PD, Smiddy P, et al., The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS, Neurology, 2001;57:2185-90.
46. Bagnato F, Evangelou IE, Gallo A, et al., The effect of interferon-beta on black holes in patients with multiple sclerosis, Expert Opin Biol Ther, 2007;7:1079-91.
47. Gaindh D, Jeffries N, Richert N, et al., The role of interferon beta 1 b in decreasing lesions size in patients with multiple sclerosis, Expert Opin Biol Ther, 2008;12:1823-9.
48. Richert ND, Ostuni JL, Bash CN, et al., Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis, Mult Scler, 2001;7:49-58.
49. Barkhof F, Van Waesberghe JH, Filippi M, et al., T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment, Brain, 2001;124:1396-402.
50. Molyneux PD, Kappos L, Polman C, et al., The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis, Brain, 2000;123:2256-63.
51. Frank JA, Richert N, Bash C, et al., Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in Nab and Nab patients, Neurology, 2004;62:719-25.
52. Inglese M, van Waesberghe JH, Rovaris M, et al., The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS, Neurology, 2003;60:853-60.
53. Richert ND, Howard T, Frank JA, et al., Relationship between inflammatory atrophy and cerebral atrophy in multiple sclerosis, Neurology, 2006;66:551-6.
54. Galetta SL, Markowitz C, US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles, CNS Drugs, 2005;19:239-52.
55. Lam S, Wang S, Gottesman M, Interferon-beta1b for the treatment of multiple sclerosis, Expert Opin Drug Metab Toxicol, 2008;4:1111-7.
56. Paolicelli D, Direnzo V, Trojano M, Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis, Biologics, 2009;3:369-76.
57. Reder AT, Ebers GC, Traboulsee A, et al., Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS, Neurology, 2010;74:1877-85.
58. Schwartz CE, Coulthard-Morris L, Cole B, et al., The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis, Arch Neurol, 1997;54:1475-80.
59. Rice GP, Oger J, Duquette P, et al., Treatment with interferon beta-1b improves quality of life in multiple sclerosis, Can J Neurol Sci, 1999;26:276-82.
60. Lily O, McFadden E, Hensor E, et al., Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment, Mult Scler, 2006;12:808-13.
61. Bagnato F, Riva M, Antonelli G, The role of neutralizing antibodies in patients with multiple sclerosis, Expert Opin Biol Ther, 2006;6:773-85.
62. Deisenhammer F, Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes, CNS Drugs, 2009;23:379-96.
63. Polman CH, Bertolotto A, Deisenhammer F, et al., Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis, Lancet Neurol, 2010;9:740-50.